-
公开(公告)号：US11278502B2
公开(公告)日：2022-03-22
申请号：US16146237
申请日：2018-09-28
申请人： LUPIN LIMITED
IPC分类号： A61K9/50 , A61K47/38 , A61K31/165 , A61K9/20 , A61K47/32
摘要： The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.
-
公开(公告)号：US09931405B2
公开(公告)日：2018-04-03
申请号：US14611578
申请日：2015-02-02
申请人： LUPIN LIMITED
IPC分类号： A61K9/14 , A61K47/44 , A61K38/12 , A61K31/196 , A61K31/785 , A61K31/197 , A61K31/4402 , A61K47/38 , A61K47/34 , A61K47/32 , A61K9/00 , A61K9/20 , A61K9/24 , A61K31/437 , A61K31/606 , A61K31/635 , A61K31/655 , A61K9/16
CPC分类号： A61K47/44 , A61K9/0065 , A61K9/0095 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2086 , A61K9/209 , A61K31/196 , A61K31/197 , A61K31/437 , A61K31/4402 , A61K31/606 , A61K31/635 , A61K31/655 , A61K31/785 , A61K38/12 , A61K47/32 , A61K47/34 , A61K47/38
摘要： A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract. A multilayered composition with active in a layer which provides immediate release or controlled release of active principles and layer providing increased residence time in the GI tract.
-
公开(公告)号：US20190192490A1
公开(公告)日：2019-06-27
申请号：US16200303
申请日：2018-11-26
申请人： Lupin Limited
IPC分类号： A61K31/437 , A23L27/00 , A61K31/428 , A61K9/10
CPC分类号： A61K31/437 , A23L27/00 , A23V2002/00 , A61K9/10 , A61K31/428
摘要： A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.
-
公开(公告)号：US20150017242A1
公开(公告)日：2015-01-15
申请号：US14379608
申请日：2013-02-14
申请人： Lupin Limited
发明人： Ashish Ashokrao Deshmukh , Hemant Bhalerao , Pravin Meghrajji Bhutada , Sajeev Chandran , Shirishkumar Kulkarni
IPC分类号： A61K31/343 , A61K9/24
CPC分类号： A61K31/343 , A61K9/209
摘要： The present invention relates to multi component composition of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of multi component composition of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per day.
摘要翻译： 本发明涉及决奈达隆或其药学上可接受的盐，酯，代谢物，前药或对映异构体和控制释放聚合物的多组分组合物。 使用多组分组合物的决奈达隆将提高生物利用度和患者依从性减少每天需要服用的剂量。
-
公开(公告)号：US10137114B2
公开(公告)日：2018-11-27
申请号：US14937730
申请日：2015-11-10
申请人： Lupin Limited
IPC分类号： A61K31/437 , A61K9/10 , A61K31/428 , A23L27/00
摘要： A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.
-
公开(公告)号：US09820936B2
公开(公告)日：2017-11-21
申请号：US15207562
申请日：2016-07-12
申请人： LUPIN LIMITED
IPC分类号： A61K9/00 , A61K9/20 , A61K9/24 , A61K9/28 , A61K31/4545
CPC分类号： A61K9/0053 , A61K9/0004 , A61K9/2018 , A61K9/2054 , A61K9/2072 , A61K9/2086 , A61K9/209 , A61K9/2846 , A61K9/2866 , A61K31/4545
摘要： The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria.
-
公开(公告)号：US20190029968A1
公开(公告)日：2019-01-31
申请号：US16146237
申请日：2018-09-28
申请人： LUPIN LIMITED
IPC分类号： A61K9/50 , A61K47/38 , A61K47/32 , A61K9/20 , A61K31/165
摘要： The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.011 秒)
